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One explanation of the increased protease activity is an
imbalance of the regulatory mechanisms. Several investi-
gators have looked for a decrease in or an abnormal func-
tion of -1-antitrypsin as a primary candidate, but variable
results have been obtained as to its role in the formation
of AAA.24,25 Other investigators have looked at the role of
tissue inhibitors of MMPs but again without consistent
results in terms of altered level.26-28 Finally, our laboratory
has shown an overall reduced elastase inhibitory capacity
in patients with AAA as opposed to controls.29
An increasing realization exists that AAA may be in
part the result of an inflammatory response to an as yet
undefined stimulus within the aortic wall. Koch et al30 in
1990 identified inflammatory cells within the aneurysm
wall, and since then, increasing evidence has been seen
that the inflammatory process is important in the ongoing
process of aneurysmal degeneration.9,31,32 This includes
the presence of immunoglobulins32,33 and cytokines in the
aortic wall and elevated plasma cytokines.34,35 The influx
of immune cells also has been seen to correlate with
increased enzyme activity in an animal model of aneurysm
disease.36
After inflammatory AAA repair, a significant percent
of patients have been observed to have the retroperitoneal
fibrosis associated with this disease entity resolve.37 One
investigator has shown the reduction of MMP-9 plasma
levels after open surgical repair of AAA in a small group of
patients.13 Our laboratory has shown an overall reduction
of elastase activity after open surgical repair as well
(unpublished data; Fig 1). These two observations also
Abdominal aortic aneurysms (AAAs) are the 13th
leading cause of death in the United States and are respon-
sible for 0.8% of all deaths. The exact mechanisms of AAA
development are unknown and likely multifactorial.
However, the most obvious pathologic feature is the loss
of the elastin in the media.1,2 Elevated proteolytic activity
has been proposed to be one of the key factors in the ini-
tiation and development of AAA.2-9 This has lead to a sig-
nificant body of research that has revealed increased
proteolytic activity seen both in aortic tissue and in plasma
of patients with AAA. This proteolytic activity involves
both serine proteases and matrix metalloproteinases
(MMPs).10-19 The growth of AAA may also be related to
varying levels of proteolytic activity. Our laboratory has
shown variation in enzyme activity of both elastases and
collagenases with size of the aneurysm.20 Other groups
have shown changes in MMP-9 levels with increasing
size.13,21-23
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Background: Abdominal aortic aneurysm (AAA) disease is a complex degenerative process that is associated with ele-
vated proteolytic activity. This increased proteolytic activity may be linked to an imbalance in the protease regulatory
mechanisms. We hypothesize that reduced AAA plasma inhibitory capacity is related to increased elastolytic activity
observed in patients with AAA, which promotes matrix degradation in the aortic wall and AAA expansion.
Methods: Preoperative plasma from patients with AAA (n = 86; mean age, 75 ± 8 years) and healthy controls (n = 30;
mean age, 72 ± 10 years) was assayed for inhibitory capacity. Postoperative plasma inhibitory capacity was evaluated
with comparison of the activity of porcine pancreatic elastase on succinylated elastin substrate, in the presence and
absence of AAA and control plasma.
Results: AAA plasma showed a significantly reduced capacity to inhibit porcine pancreatic elastase (71.31% ± 1.47%)
compared with control plasma (85.52% ± 1.70%; P < .001). Within the AAA group, the inhibitory capacity increased
with AAA diameter (P < .05). In addition, surgical repair of AAA resulted in a significant increase in plasma inhibitory
capacity (79.83% ± 1.86%) as compared with preoperative levels (63.98% ± 2.69%; P < .001). Of note, the postopera-
tive plasma inhibitory capacity is not significantly different than that of control.
Conclusion: AAA plasma has a significantly reduced inhibitory capacity, which varies with aortic diameter and returns
to control levels after surgical repair of the AAA. This suggests that protease regulation is a dynamic balance that
changes with AAA progression and may play an important role in AAA progression. (J Vasc Surg 2002;35:792-7.)
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suggest that exclusion of the aneurysm sac removes the
stimulus for perpetuating the inflammatory response that
leads to matrix degeneration.
The purpose of this study is to analyze the general
elastase inhibitory capacity in patients with AAA as com-
pared with age-matched controls in terms of alteration
with AAA size. In addition, we proposed that the
inhibitory capacity would be restored after open surgical
repair.
METHODS
Patient selection and plasma collection. With
Institutional Review Board approval, during a 3.5-year
period (1997 to 2001), 86 patients (mean age, 75 ± 8
years) who underwent elective open AAA repair were
enrolled in this study. History was obtained to include risk
factors for vascular disease, such as smoking history, hyper-
tension, diabetes, coronary artery disease, chronic
obstructive lung disease, other aneurysms, and peripheral
vascular disease. Preoperative blood samples were col-
lected in heparinized vacuutainer tubes (Beckton Dickson,
Franklin Lakes, NJ). All patients underwent preoperative
computerized axial tomographic scanning for assessment
of the size of the AAA and for the presence of other
aneurysms. The presence or absence of popliteal
aneurysms was assessed with physical examination. The
largest diameter of the infrarenal aorta was taken to be the
size of the AAA. All AAAs were repaired with a standard
Creech technique with tube grafts and with wrapping of
the graft with the aneurysm wall.
During the same time period, 30 age-matched volun-
teers (mean age, 72 ± 10 years) without AAA, with history
and physical examination by an experienced vascular sur-
geon, were recruited for control samples. These patients
also were assessed for smoking history and evidence of
other comorbid medical conditions.
Postoperative blood samples were obtained from a
total of 31 patients who agreed to have the repeat samples
obtained. The follow-up period when the samples were
obtained ranged from 1.7 months to 43.8 months (mean,
11.7 months). Plasma was prepared from blood with cen-
trifugation and stored at –80°C until use.
Inhibition assay. The inhibition assay was on the
basis of a microassay of enzyme activity previously
described and patented in our laboratory (Fig 2).38 This
assay uses succinylated protein, which then is digested by
the enzymes in the plasma, revealing free amino groups.
This then is reacted with 2,4,6-trinitrobenzene (Pierce
Chemical Co, St Louis, Mo), which reacts with the free
amino groups. This complex absorbs at 450 nm, and the
amount absorption is proportional to the amount of pro-
tein digested and thus enzymatic activity.
For the inhibition assay,39 a solution of 100 g of suc-
cinylated elastin, 10 L of plasma, and 50 L of porcine
pancreatic elastase (PPE; EC3.4.21.36; 1 g/L made up in
50 mol/L sodium borate, pH 8.5; 297 U/mg;
Calbiochem, San Diego, Calif) was prepared. This was
made up to a final volume of 150 L with 50 mol/L
sodium borate buffer as previously described in a 96-well
microplate (Falcon 3097, Beckton Dickson). The assay
was carried out at 37°C for 30 minutes. Next, 50 L of
0.3 g/L of 2,4,6-trinitrobenzene was added and incu-
bated for 20 minutes at room temperature. The optical
density of the reaction then was measured in a spec-
trophotometer at 450 nm (Fig 3).
For each plasma sample analyzed, a blank reaction of
10 L of plasma and 50 L of PPE and buffer without
elastin substrate was performed. This allowed for assess-
ment of the intrinsic amine content of the plasma sample.
The inhibition is expressed as the percent reduction in
PPE activity seen, with 0% inhibition designated as the
activity of PPE without plasma present.
Statistics. Data regarding the comorbid conditions and
smoking history were analyzed with 2 test or Fisher exact
test. Data regarding control versus AAA inhibitory capacity
and difference between preoperative and postoperative
samples were analyzed with Student t test and one-way
analysis of variance. Data regarding variation of inhibitory
capacity in relation to aneurysm size were analyzed with
one-way analysis of variance. All statistics were performed
with the Sigma Stat statistical software (Jandel Scientific,
Chicago, Ill). All inhibitory capacity results are presented as
the mean ± the standard error of the mean. P values of less
than .05 were considered as statistically significant.
RESULTS
Patients with AAA and controls had no significant dif-
ferences in their age (75 ± 8 years versus 72 ± 10 years,
respectively) and comorbid medical conditions. In partic-
ular, there was no difference between the incidence rate of
chronic obstructive lung disease in the two groups (21% in
the AAA group versus 30% in the control group). There
was also no significant difference in the number of smok-
Fig 1. The effect of open surgical repair of AAA on elastolytic
activity. After open surgical repair, the increased elastolytic activ-
ity seen in AAA patients returns to that of controls.
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ers versus nonsmokers in both groups (33% in the AAA
group and 38% in the control group).
Patients with AAA showed a significantly reduced
plasma inhibitory capacity as compared with control vol-
unteers (71.31% ± 1.47% versus 85.52% ± 1.70%; P <
.001; Fig 3). The difference between patients with AAA
and controls remained significant even in comparison of
smokers and nonsmokers (for both groups, P < .01).
However, within the AAA group, there is no significant
difference between smokers and nonsmokers, and the
same is true of the control group (Fig 4). Plasma
inhibitory capacity of patients with AAA increased with
increasing AAA size. The difference between 3 and 4.9 cm
and between 5 and 6.9 cm was statistically significant
(62.02% ± 4.00% versus 73.17% ± 1.61%; P < .05). In
addition, larger aneurysms (>7 cm) seemed to approach
control levels, with a plasma inhibitory capacity of 75.97%
± 2.44%. The difference between healthy volunteers versus
the group with greater than 7 cm aneurysms was not sta-
tistically significant, but the difference between the 3 to
4.9–cm group and the 5 to 6.9–cm group versus control
was significantly reduced, with P < .05 (Fig 5). After open
AAA repair, the plasma inhibitory capacity returned to lev-
els comparable with that of control volunteers, with no
statistically significant difference between the plasma
inhibitory capacities of these two groups (79.83% ± 1.86%
versus 85.52% ± 1.70%; Fig 6). The postoperative
inhibitory capacity was statistically different from the pre-
operative level (63.98% ± 2.69%), with a P value of less
than .001.
DISCUSSION
The pathophysiology of AAA is complex. These data
support the concept that loss of inhibition of proteolytic
enzymes is important in the development of aneurysms.
AAA may be related to the overall loss of the ability to
inhibit the increased elastase activity that has been previ-
ously shown in both plasma and aortic tissue of patients
with AAA. The increase of inhibition seen with increasing
aneurysm diameter may be related to the loss of elastin,
thereby altering both enzymatic activity and inhibitory
capacity.40-42 Our assay favors detection of serine elastase
inhibition as the result of the use of PPE. The major
inhibitors of this elastolytic activity are still unclear, other
than -1-antitrypsin, whose role in aneurysm formation is
not well defined. Our laboratory has begun to look at
elastin-derived peptides (EDPs) as inhibitors of serine elas-
tase as a potential feedback mechanism.43 The decrease in
the production of EDPs that would occur as elastin content
decreases within the enlarging AAA may also help explain
the increase in inhibition seen with larger aneurysms.
Fig 2. Assay for protease activity, which can be applied to many substrate-enzyme combinations.
Fig 3. The AAA patients have a statistically significant reduction
in plasma inhibitory capacity as compared with that of controls (P
< .001)
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Plasma inhibitory capacity from patients with AAA
appeared to approach that of control volunteers once the
AAA was repaired with standard open technique.
Although the number of samples tested before and after
surgery is small, this correlates both to our data that show
the decrease in elastolytic activity and the data from oth-
ers that show a reduction in MMP-9 levels after open
aneurysm repair. This implies that the stimulus for ongo-
ing enzymatic activity has been removed from the circula-
tion. The fact that the levels of both enzymatic activity and
inhibitory capacity approach control levels after open
repair additionally supports the now abundant literature
that suggests a potential autoimmune cause of AAA. The
exclusion of the wall of the aneurysm from any hematoge-
nous contact would remove from circulation the stimulus
for perpetuation of the inflammatory response and thus
alterations in protease and antiprotease balance. Future
work will include a look at the individual candidate
inhibitors and enzymes. Because the role of -l-antitrypsin
had been investigated previously, our laboratory has
focused on other potential inhibitors of the serine elastase,
such as the EDPs mentioned previously.
In addition, as endovascular repair of AAA becomes
more common and the long-term fate of these repairs is
unknown, plasma proteolytic activity and inhibitory capac-
ity may prove useful in assessment of the efficacy of the
repair. In theory, if any endoleak exists, these levels should
remain abnormal. Study of these levels before and after
Fig 4. The effect of smoking on inhibitory capacity. There is a statistically significant difference between controls and AAA both in
patients who smoke and those who do not (P < .01). There is no statistical difference between smokers and nonsmokers in patients with
AAA or in the control group.
Fig 5. The effect of AAA size on inhibitory capacity. Control ver-
sus the 3 to 4.9 cm group and the 5 to 6.9 cm group both have
statistically significant differences (P < .05). The 3 to 4.9 cm
group compared with the 5 to 6.9 cm group have statistically sig-
nificant differences (P < .05). The >7 cm group was not signifi-
cantly different from that of control.
Fig 6. The effect of open surgical repair on plasma inhibitory
capacity. After open surgical repair, postoperative inhibitory
capacity is significantly increased as compared with preoperative
levels (P < .001). The postoperative level is not significantly dif-
ferent from that of controls.
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endovascular repair in conjunction with radiologic assess-
ment of endoleaks and changes in aneurysm size may lead
to the ability of prediction of long-term success of
endovascular repair with blood sampling.
CONCLUSION
Plasma from patients with AAA has a significantly
reduced elastase inhibitory capacity compared with that
of controls. Plasma inhibitory capacity of patients with
AAA improves with increasing size, and aneurysms of
greater than 7 cm have levels similar to that of controls.
Open operative repair of AAA appears to reverse the
loss of inhibitory capacity seen with AAAs. In fact,
inhibitory capacity returns to levels comparable with
those of controls.
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